Hypokalemia is a well-described electrolyte disturbance in patients on peritoneal dialysis (PD). Hyperkalemia, however, is still overlooked, although it also represents a risk factor for mortality. Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (ACE/ARB), diuretics, and proton pump inhibitor (PPI) can interfere with potassium levels in these patients.
This is a retrospective study that evaluated monthly serum potassium in a 5-year period. Serum potassium disturbances were evaluated as time-average and number of hypo- and hyperkalemia episodes per patient. Prescribed medication such as ACE/ARB, diuretics, and omeprazole were recorded.
We evaluated 2025 potassium measurements obtained from 146 patients on PD. Serum potassium ranged from 2.5 to 8.3 mEq/L with an average of 4.72 ± 0.74 mEq/L. Hypokalemia was found in 59 measurements (2.9%) obtained from 35 patients (23.9%) whereas hyperkalemia was demonstrated in 269 (13.3%) measurements obtained from 74 patients (50.7%). Hypokalemia was associated with low albumin (p = 0.022), and omeprazole use (p = 0.024). Black race was a protector factor (p = 0.031). Omeprazole-associated hypokalemia was seen only in non-anuric patients and remained an independent risk factor even after adjustments. Patients who had hyperkalemia were more likely to be anuric (p = 0.001) and in use of furosemide (p = 0.0001).
Hyperkalemia and hypokalemia are very frequent in patients on PD and should be closely monitored. Interventional studies should address the impact of discontinuing omeprazole in the levels of potassium.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Ribeiro SC, Figueiredo AE, Barretti P, Pecoits-Filho R, de Moraes TP, All centers that contributed to BIIs (2015) Low serum potassium levels increase the infectious-caused mortality in peritoneal dialysis patients: a propensity-matched score study. PLoS ONE 10(6):e0127453. https://doi.org/10.1371/journal.pone.0127453
Xu Q, Xu F, Fan L, Xiong L, Li H, Cao S, Lin X, Zheng Z, Yu X, Mao H (2014) Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality. PLoS ONE 9(1):e86750. https://doi.org/10.1371/journal.pone.0086750
Chuang YW, Shu KH, Yu TM, Cheng CH, Chen CH (2009) Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients. Nephrol Dial Transplant 24(5):1603–1608. https://doi.org/10.1093/ndt/gfn709
Jung JY, Chang JH, Lee HH, Chung W, Kim S (2009) De novo hypokalemia in incident peritoneal dialysis patients: a 1-year observational study. Electrolyte Blood Press 7(2):73–78. https://doi.org/10.5049/EBP.2009.7.2.73
Yu HL, Lu XH, Su CY, Tang W, Wang T (2014) Potassium metabolism in continuous ambulatory peritoneal dialysis patients. Ren Fail 36(5):748–754. https://doi.org/10.3109/0886022X.2014.884379
Fulop T, Zsom L, Rodriguez B, Afshan S, Davidson JV, Szarvas T, Dixit MP, Tapolyai MB, Rosivall L (2017) Clinical utility of potassium-sparing diuretics to maintain normal serum potassium in peritoneal dialysis patients. Perit Dial Int 37(1):63–69. https://doi.org/10.3747/pdi.2016.00022
Torlen K, Kalantar-Zadeh K, Molnar MZ, Vashistha T, Mehrotra R (2012) Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol 7(8):1272–1284. https://doi.org/10.2215/CJN.00960112
Kim HW, Chang JH, Park SY, Moon SJ, Kim DK, Lee JE, Han SH, Kim BS, Kang SW, Choi KH, Lee HY, Han DS (2007) Factors associated with hypokalemia in continuous ambulatory peritoneal dialysis patients. Electrolyte Blood Press 5(2):102–110. https://doi.org/10.5049/EBP.2007.5.2.102
Szeto CC, Chow KM, Kwan BC, Leung CB, Chung KY, Law MC, Li PK (2005) Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication. Am J Kidney Dis 46(1):128–135
Salenger PV (2019) Sudden cardiac death in end-stage renal disease. Cardiol Clin 37(3):319–326. https://doi.org/10.1016/j.ccl.2019.04.010
Poulikakos D, Hnatkova K, Skampardoni S, Green D, Kalra P, Malik M (2019) Sudden cardiac death in dialysis: arrhythmic mechanisms and the value of non-invasive electrophysiology. Front Physiol 10:144. https://doi.org/10.3389/fphys.2019.00144
Wang AY, Brimble KS, Brunier G, Holt SG, Jha V, Johnson DW, Kang SW, Kooman JP, Lambie M, McIntyre C, Mehrotra R, Pecoits-Filho R (2015) ISPD Cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part II—management of various cardiovascular complications. Perit Dial Int 35(4):388–396. https://doi.org/10.3747/pdi.2014.00278
Franczyk-Skora B, Gluba-Brzozka A, Wranicz JK, Banach M, Olszewski R, Rysz J (2015) Sudden cardiac death in CKD patients. Int Urol Nephrol 47(6):971–982. https://doi.org/10.1007/s11255-015-0994-0
Palmer BF, Clegg DJ (2018) Hyperkalemia across the continuum of kidney function. Clin J Am Soc Nephrol 13(1):155–157. https://doi.org/10.2215/CJN.09340817
Ribeiro SC, Figueiredo AE, Barretti P, Pecoits-Filho R, de Moraes TP, Investigators B (2017) Impact of renin-angiotensin aldosterone system inhibition on serum potassium levels among peritoneal dialysis patients. Am J Nephrol 46(2):150–155. https://doi.org/10.1159/000479011
Garthwaite E, Bhandari S (2009) The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function. Artif Organs 33(8):641–647. https://doi.org/10.1111/j.1525-1594.2009.00790.x
Phakdeekitcharoen B, Leelasa-nguan P (2004) Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis 44(4):738–746
Wong CM, O'Connor DT, Martinez JA, Kailasam MT, Parmer RJ (2003) Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension. Am J Hypertens 16(4):281–289. https://doi.org/10.1016/s0895-7061(03)00002-5
Chen Y, Sang Y, Ballew SH, Tin A, Chang AR, Matsushita K, Coresh J, Kalantar-Zadeh K, Molnar MZ, Grams ME (2017) Race, serum potassium, and associations with ESRD and mortality. Am J Kidney Dis 70(2):244–251. https://doi.org/10.1053/j.ajkd.2017.01.044
Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP (2012) Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract 120(1):c8–16. https://doi.org/10.1159/000329511
Vavruk AM, Martins C, Nascimento MM, Hayashi SY, Riella MC (2012) Association between hypokalemia, malnutrition and mortality in peritoneal dialysis patients. J Bras Nefrol 34(4):349–354
Zanger R (2010) Hyponatremia and hypokalemia in patients on peritoneal dialysis. Semin Dial 23(6):575–580. https://doi.org/10.1111/j.1525-139X.2010.00789.x
Jaynes M, Kumar AB (2019) The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf 10:2042098618809927. https://doi.org/10.1177/2042098618809927
Epstein M, McGrath S, Law F (2006) Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 355(17):1834–1836. https://doi.org/10.1056/NEJMc066308
Cundy T, Dissanayake A (2008) Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 69(2):338–341. https://doi.org/10.1111/j.1365-2265.2008.03194.x
Francois M, Levy-Bohbot N, Caron J, Durlach V (2008) Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris) 69(5):446–448. https://doi.org/10.1016/j.ando.2008.03.003
Fatuzzo P, Portale G, Scollo V, Zanoli L, Granata A (2017) Proton pump inhibitors and symptomatic hypomagnesemic hypoparathyroidism. J Nephrol 30(2):297–301. https://doi.org/10.1007/s40620-016-0319-0
Maeda Y, Kojima N, Araki Y, Uno T, Nishigaki K, Inaba N (2011) Does a proton pump inhibitor cause hypokalemia? Intern Med 50(9):1045–1050. https://doi.org/10.2169/internalmedicine.50.4877
We thank Fatima Libanio for her assistance with electronic data collection.
RMAM and RME are supported by CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico (Grant Numbers 304249/2013-0 and 305106/2018-0, respectively). This financial support had no role in study design; collection, analysis and interpretation of data; writing the report; and the decision to submit the report for publication.
Conflict of interest
We have read and understood Peritoneal Dialysis International’s policy on disclosing conflicts of interest and declare that we have none.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Goncalves, F.A., de Jesus, J.S., Cordeiro, L. et al. Hypokalemia and hyperkalemia in patients on peritoneal dialysis: incidence and associated factors. Int Urol Nephrol 52, 393–398 (2020). https://doi.org/10.1007/s11255-020-02385-2
- Proton-pump inhibitor
- Black race